Skip to main content
OpenTrials
Completed

NCT Number: NCT04585399

Increasing MAT Engagement With Financial Incentives

The increased prevalence of opioid use disorder (OUD) and associated overdoses and adverse events has led to a substantial increase in the number of patients being seen at emergency departments (ED). Thus, the ED may be an ideal location for identifying patients in need of OUD treatment and can serve as the first touch point in the OUD continuum of care to promote medication assisted treatment initiation. Contingency management (CM) is an effective method for promoting treatment initiation and adherence that has not been thoroughly evaluated for this purpose. The primary aim of the current study is to develop and assess the effectiveness, acceptability, and feasibility of a protocol for delivering CM to increase combined buprenorphine + nalaxone (referred to as BUP hereafter) initiation and continuous adherence for OUD in an existing ED "bridge" program (e.g., Bridge plus CM; B+CM) relative to standard care. Secondary objectives include identifying behavioral and neuropsychological correlates to treatment outcomes, including delay discounting, reinforcer demand, and neurological soft signs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Opioid-use Disorder Chemically-Induced Disorders Mental Disorders Narcotic-Related Disorders Opioid-Related Disorders Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cooper University Hospital

Camden, New Jersey, 08108, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants at least 18 years of age
  • Participants must be newly enrolled in the Bridge program in the Cooper University ED, with their first clinic appointment scheduled to take place at the Cooper Outreach Clinic within one week of enrollment.
  • All subjects must be in good physical health as determined by a physical examination and premenopausal women will have a pregnancy test on the day of the study to rule out pregnancy

Exclusion criteria

  • Participants who demonstrate contraindication with Suboxone treatment or who are currently or have recently used other medication-assisted therapies for opioid use disorder.
  • Participants who are currently pregnant or breastfeeding or have been diagnosed with a DSM-5 psychiatric condition that might interfere with treatment delivery (e.g., uncontrolled schizophrenia, bipolar disorder, dementia)
  • Participants who are non-English speaking or cannot otherwise provide valid informed consent.
  • Individuals who are unable to complete the survey assessments, due to literacy or visual impairments.
  • The participant will not be a prisoner

Treatment and study plan

Contingency Management

Behavioral

Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.

Primary outcomes

  1. Attendance at first scheduled clinic appointment

    Time frame: 1 week

    We will track attendance at participant's first scheduled BUP appointment after being bridged from the ED

  2. Percentage of sessions where buprenorphine positive urine results was recorded

    Time frame: 3-months

    Urine-verified buprenorphine

  3. Percentage of sessions where opioid free urine results were recorded

    Time frame: 3-months

    Urine-verified opioid abstinence

  4. Treatment acceptability

    Time frame: 3-months

    Participants will evaluate the treatment at the end.

Secondary outcomes

  1. Delay discounting as a correlate of opioid-free urine test results and buprenorphine-positive results

    Time frame: 3-months

    Delay discounting will be evaluated, using the brief, five question delay discounting procedure and will be correlated with urine results determining opioid abstinence and buprenorphine adherence.

  2. Opioid demand as a correlate of opioid-free urine test results and buprenorphine-positive results

    Time frame: 3-months

    The opioid purchasing task will be used to evaluate opioid demand and will be correlated with urine results determining opioid abstinence and buprenorphine adherence.

  3. Substance-free activities as a correlate of opioid-free urine test results and buprenorphine-positive results

    Time frame: 3-months

    A modified Pleasant Events Scale survey will be used to evaluate access to, and enjoyment from, substance-free activities and the results will be correlated with urine results determining opioid abstinence and buprenorphine adherence.

  4. Neurological Soft Signs correlate with treatment success

    Time frame: 3-months

    Participants will complete a drawing task that has been correlated with other substance use treatment outcomes in the past.

Sponsors and collaborators

Lead sponsor

Rowan University

Other

Collaborators

  • The Cooper Health System

Registry information

Official study title

Increasing MAT Engagement With Contingency Management Among Individuals With Opioid Use Disorder in an ED Bridge Program

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Oct 14, 2020
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.